BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors
BD (NYSE: BDX) announced the appointment of Robert Huffines and Jacqueline Wright to its board of directors, effective Dec. 1, 2025. The company said the additions add expertise in health care, technology, digital transformation, artificial intelligence, finance and capital markets as BD advances its strategy to be a scaled pure‑play medical technology company. BD added three new independent directors in 2025, reflecting ongoing board refreshment. Bios note Huffines' 30+ years in healthcare investment banking and board service, and Wright's 30+ years in technology and digital transformation at McKinsey and Microsoft.
BD (NYSE: BDX) ha annunciato la nomina di Robert Huffines e Jacqueline Wright al consiglio di amministrazione, con effetto 1 dicembre 2025. L'azienda ha dichiarato che gli ingressi aggiungono competenze in sanità, tecnologia, trasformazione digitale, intelligenza artificiale, finanza e mercati dei capitali mientras BD avanza nella sua strategia per diventare una società di tecnologia medica di scala come pure-play. BD ha aggiunto tre nuovi direttori indipendenti nel 2025, a riflettere un continuo rinnovo del consiglio. Le biografie indicano i oltre 30 anni di Huffines nel settore della banca d'investimento sanitario e nel servizio al consiglio, e i oltre 30 anni di Wright in tecnologia e trasformazione digitale presso McKinsey e Microsoft.
BD (NYSE: BDX) anunció la designación de Robert Huffines y Jacqueline Wright para su junta directiva, con efecto 1 de diciembre de 2025. La empresa indicó que las incorporaciones aportan experiencia en atención sanitaria, tecnología, transformación digital, inteligencia artificial, finanzas y mercados de capitales mientras BD avanza su estrategia para convertirse en una empresa tecnológica médica de escala como negocio puro. BD añadió tres nuevos directores independientes en 2025, reflejando una renovación continua de la junta. Las biografías señalan los más de 30 años de Huffines en banca de inversión sanitaria y servicio a la junta, y los más de 30 años de Wright en tecnología y transformación digital en McKinsey y Microsoft.
BD (NYSE: BDX)는 이사회에 로버트 허핀스와 재클린 라이트를 임명했다고 발표했으며, 발효일은 2025년 12월 1일입니다. 회사는 이 추가 인사가 의료 서비스, 기술, 디지털 트랜스포메이션, 인공지능, 금융 및 자본시장에 대한 전문성을 더할 것이며 BD가 규모가 큰 순수 의료기술 회사로서의 전략을 추진하고 있다고 밝혔습니다. BD는 2025년에 세 명의 새로운 독립 이사를 선임했고, 이는 이사회의 지속적인 갱신을 반영합니다. 약력에는 허핀스의 의료 투자 은행업 및 이사회 경력 30년 이상, 그리고 라이트의 기술 및 디지털 트랜스포메이션 분야에서의 맥킨지와 마이크로소프트 경력이 30년 이상이라고 적혀 있습니다.
BD (NYSE: BDX) a annoncé la nomination de Robert Huffines et Jacqueline Wright au conseil d'administration, avec effet le 1er décembre 2025. L'entreprise a déclaré que ces ajouts apportent une expertise en soin de santé, technologie, transformation numérique, intelligence artificielle, finance et marchés de capitaux alors que BD fait progresser sa stratégie pour devenir une entreprise technologique médicale pure et évolutive. BD a ajouté trois nouveaux administrateurs indépendants en 2025, ce qui reflète le renouvellement continu du conseil. Les bios mentionnent plus de 30 années d'expérience de Huffines dans la banque d'investissement en santé et au conseil, et plus de 30 années pour Wright dans la technologie et la transformation numérique chez McKinsey et Microsoft.
BD (NYSE: BDX) hat die Berufung von Robert Huffines und Jacqueline Wright in den Vorstand bekannt gegeben, gültig ab 1. Dezember 2025. Das Unternehmen sagte, dass die Ergänzungen Fachwissen in Gesundheitswesen, Technologie, digitale Transformation, Künstliche Intelligenz, Finanzen und Kapitalmärkten hinzufügen, während BD seine Strategie vorantreibt, ein skalierendes reines Medizintechnikunternehmen zu werden. BD fügte 2025 drei neue unabhängige Direktoren hinzu, was eine laufende Erneuerung des Vorstands widerspiegelt. Die Bios vermerken Huffines' über 30 Jahre Erfahrung im Gesundheitswesen-Investmentbanking und Vorstandsarbeit sowie Wrights über 30 Jahre in Technologie und digitaler Transformation bei McKinsey und Microsoft.
BD (NYSE: BDX) أعلنت عن تعيين روبرت هافينس وجاكلين رايت في مجلس إدارتها، اعتباراً من 1 ديسمبر 2025. قالت الشركة إن هذه الإضافات تضيف خبرة في الرعاية الصحية، التكنولوجيا، التحول الرقمي، الذكاء الاصطناعي، المالية وأسواق رأس المال بينما تتقدم BD في استراتيجيتها لتكون شركة تكنولوجيا طبية متخصصة وقابلة للتوسع. أضافت BD ثلاثة مديرين مستقلين جدد في 2025، مما يعكس تجديد المجلس المستمر. تشير السير الذاتية إلى أكثر من 30 عاماً من الخبرة لدى هافينز في الخدمات المصرفية الاستثمارية للرعاية الصحية وخدمة المجلس، وقرابة 30 عاماً لدى رايت في التكنولوجيا والتحول الرقمي في ماكينزي ومايكروسوفت.
- Adds two directors effective Dec. 1, 2025
- Board now has three new independent directors in 2025
- New directors bring healthcare, tech, AI, finance expertise
- None.
"Robbie and Jacky will further strengthen the BD board with deep expertise in health care, technology, digital transformation and artificial intelligence, as well as finance and capital markets, all of which are core to the continued advancement of our strategy," said Tom Polen, chairman, CEO and president of BD. "Their global leadership and extensive experience will be invaluable as we advance New BD as a scaled pure-play innovative medical technology company, unlocking meaningful value for BD shareholders while advancing our impact on patients and health systems."
"With its scale, innovation and unwavering commitment to improving health care delivery, BD is shaping the future of medical technology," said Robert Huffines. "As the company enters this next chapter, I'm eager to support BD in delivering lasting value for our patients, employees and shareholders."
"For over a century, BD has played a critical role in patient care," said Jacqueline Wright. "As BD continues its legacy, I look forward to working with the rest of the board and management team, supported by continued digital transformation, to shape the evolving the health care landscape and significantly improve patient care globally."
The Company has added three new independent directors in 2025, continuing its commitment to strong corporate governance and regular board refreshment.
Robert Huffines
Robert Huffines brings more than three decades of experience advising health care companies on strategy, mergers and acquisitions, divestitures and financing. Huffines is a former global chairman of investment banking at J.P. Morgan Chase & Co. He joined J.P. Morgan in 1991 and held several leadership roles, including co-head of the global health care investment banking group, vice chairman and co-chair of the global strategic advisory council. Prior to joining J.P. Morgan, Huffines worked at Alex Brown & Sons, specializing in equity financing and advisory assignments for emerging growth companies.
Mr. Huffines currently serves on the Board of Directors of Insulet Corporation. He also served as a director of Walgreens Boots Alliance until its sale in August 2025. In 2023, Huffines co-founded The Forest Group, Inc., a non-profit organization focused on improving the mental health of children in underserved communities. He is also a board member of the Hastings Center for Biomedical Ethics, Nextech Invest Ltd. and Eikon Therapeutics.
Huffines received a bachelor's degree in English and economics from the University of
Jacqueline Wright
Jacqueline Wright, brings more than 30 years of experience in technology and digital transformation. She most recently served as the first chief technology and platform officer at McKinsey & Company, a global management consulting firm, where as a senior partner, she led the firm's overall technology portfolio and strategy. Prior to joining McKinsey, Wright spent over a decade at Microsoft Corporation in various roles, including chief digital officer,
Wright currently serves on the Board of Directors of Frasers Group Plc and Russell Reynolds Associates, Inc. and previously served as a board member for Exelixis, Inc. and nVent Electric plc. Wright received a bachelor's degree in Computer Information Systems and Accounting from the Bernard M. Baruch College, City University of
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
|
Contacts: |
|
|
Media: |
Investors: |
|
Fallon Mcloughlin |
Adam Reiffe |
|
Director, Public Relations |
Vice President, Investor Relations |
|
201-258-0361 |
201-847-6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-appoints-robert-huffines-and-jacqueline-wright-to-board-of-directors-302616297.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
Who are the new directors appointed to BD's board effective Dec. 1, 2025 (BDX)?
What experience does Robert Huffines bring to BD (NYSE: BDX)?
What is Jacqueline Wright's background relevant to BD (BDX)?
How do these board changes affect BD's governance in 2025 (BDX)?
When did BD announce the board appointments and where can investors find contact information (BDX)?
